Literature DB >> 7898706

Comparison of therapeutic efficacies of type A and F botulinum toxins for blepharospasm: a double-blind, controlled study.

T Mezaki1, R Kaji, N Kohara, H Fujii, M Katayama, T Shimizu, J Kimura, M F Brin.   

Abstract

Type F botulinum toxin can be used for treating patients with dystonia who become refractory to type A toxin injection due to antibody development. We compared the therapeutic efficacy of type F botulinum toxin to that of type A toxin in a self-controlled, double-blind clinical trial. In nine patients with blepharospasm, we injected type A toxin on one side and the same units of type F toxin on the other side. Although the onset of clinical effect, maximal benefit, and adverse reactions were similar between type A and F toxins, the duration of the clinical effect was significantly shorter on the side injected with type F toxin. Although type F toxin proved its promise as an alternative to type A toxin, its usefulness is limited by the shorter duration of action.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7898706     DOI: 10.1212/wnl.45.3.506

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  12 in total

1.  Clinical use of non-A botulinum toxins: botulinum toxin type C and botulinum toxin type F.

Authors:  R Eleopra; V Tugnoli; R Quatrale; O Rossetto; C Montecucco; D Dressler
Journal:  Neurotox Res       Date:  2006-04       Impact factor: 3.911

Review 2.  The blockade of the neurotransmitter release apparatus by botulinum neurotoxins.

Authors:  Sergio Pantano; Cesare Montecucco
Journal:  Cell Mol Life Sci       Date:  2013-06-11       Impact factor: 9.261

3.  Further studies using higher doses of botulinum toxin type F for torticollis resistant to botulinum toxin type A.

Authors:  M K Houser; G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

Review 4.  Guidelines for the therapeutic use of botulinum toxin in movement disorders. Italian Study Group for Movement Disorders, Italian Society of Neurology.

Authors:  A Berardelli; G Abbruzzese; L Bertolasi; G Cantarella; F Carella; A Currà; D De Grandis; G DeFazio; G Galardi; P Girlanda; P Livrea; N Modugno; A Priori; G Ruoppolo; L Vacca; M Manfredi
Journal:  Ital J Neurol Sci       Date:  1997-10

5.  Costs of treating dystonias and hemifacial spasm with botulinum toxin A.

Authors:  R C Dodel; A Kirchner; R Koehne-Volland; G Künig; A Ceballos-Baumann; M Naumann; A Brashear; H P Richter; T D Szucs; W H Oertel
Journal:  Pharmacoeconomics       Date:  1997-12       Impact factor: 4.981

6.  Botulinum toxin type A therapy for blepharospasm.

Authors:  Gonçalo S Duarte; Filipe B Rodrigues; Raquel E Marques; Mafalda Castelão; Joaquim Ferreira; Cristina Sampaio; Austen P Moore; João Costa
Journal:  Cochrane Database Syst Rev       Date:  2020-11-19

7.  Botulinum toxin F in the treatment of torticollis clinically resistant to botulinum toxin A.

Authors:  G L Sheean; A J Lees
Journal:  J Neurol Neurosurg Psychiatry       Date:  1995-12       Impact factor: 10.154

Review 8.  Botulinum toxin: bioweapon & magic drug.

Authors:  Ram Kumar Dhaked; Manglesh Kumar Singh; Padma Singh; Pallavi Gupta
Journal:  Indian J Med Res       Date:  2010-11       Impact factor: 2.375

Review 9.  Targeted secretion inhibitors-innovative protein therapeutics.

Authors:  Foster Keith; Chaddock John
Journal:  Toxins (Basel)       Date:  2010-12-03       Impact factor: 4.546

10.  Zebrafish Sensitivity to Botulinum Neurotoxins.

Authors:  Kamalakar Chatla; Patricia S Gaunt; Lora Petrie-Hanson; Lorelei Ford; Larry A Hanson
Journal:  Toxins (Basel)       Date:  2016-05-03       Impact factor: 4.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.